BACKGROUND: @entity1072 ( @entity1072 ) @entity1 are at high risk for acute @entity1576 ( @entity10916 ). OBJECTIVE: We evaluated the safety and efficacy of a proprietary extract of Panax quinquefolius, @entity19312 , in reducing @entity10916 . METHODS: This was a double-blind, placebo-controlled, randomized trial of 293 subjects with early-stage, untreated @entity1072 conducted January-March 2009. RESULTS: @entity10916 was common, occurring on about 10% of days during the study period. There were no significant differences of the 2 a priori primary end points: @entity10916 days (8.5    17.2 for @entity19312 vs 6.8    13.3 for placebo) and severe @entity10916 days (2.9    9.5 for @entity19312 vs 2.6    9.8 for placebo). However, 51% of @entity19312 vs 56% of placebo recipients experienced at least 1 @entity10916 (difference, -5%; 95% confidence interval [CI], -16% to 7%); more intense @entity10916 occurred in 32% of @entity19312 vs 39% of placebo recipients (difference, -7%; 95% CI, -18% to 4%), and symptom-specific evaluation showed reduced moderate to severe sore throat (P = .004) and a lower rate of grade >= 3 @entity137 (P = .02) in @entity19312 recipients. Greater seroconversion (4-fold increases in antibody titer) vs 9 common viral pathogens was documented in @entity19312 recipients (16% vs 7%, P = .04). LIMITATIONS: Serologic evaluation of antibody titers was not tied to a specific illness, but covered the entire study period. CONCLUSION: @entity19312 was well tolerated. It did not reduce the number of @entity10916 days or antibiotic use; however, there was a trend toward reduced rates of moderate to severe @entity10916 and significantly less sore throat, suggesting that the increased rate of seroconversion most likely reflects @entity19312 -enhanced antibody responses.

A randomized, controlled trial of Panax quinquefolius extract ( @entity19312 ) to reduce respiratory infection in @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity1072 :: ('MESH:D015451', 'Disease') :: ['CLL', 'Chronic lymphocytic leukemia'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory illness'] @entity19312 :: ('MESH:C536345', 'Disease') :: ['CVT-E002'] @entity10916 :: ('CHEBI:35640', 'Chemical') :: ['ARI']
@entity1072 :: (MESH:D015451,Disease) :: ['chronic lymphocytic leukemia']
